The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care (PREVENT)

June 27, 2025 updated by: Alexandra Papaioannou, McMaster University
Hip fractures occur nearly twice as often for older adults residing in long-term care as they do in older adults of a similar age still living in other settings. Hip fractures are the leading cause of hospitalization and often result in loss of independence, problems with walking and sometimes death. To address this problem the PREVENT (Person-centered Routine Fracture PrEVENTion in LTC) program was designed for use in long-term care homes. PREVENT uses a tool ("fracture risk calculator") based on a residents electronic health record to capture who is most at risk of fracture due to osteoporosis and falls. The program then trains the health care team including doctors, pharmacists and nurses on the latest recommendations on how to best assist residents and their families in making treatment decisions. The healthcare teams are also given tools that help them stay on track such as templates for ordering medications, strategies to reduce falls and fractures and making care plans. The study will examine if this program is effective for decreasing hip fractures by assigning some homes to receive the PREVENT program (intervention group) and some homes to usual care (control group) and comparing the results.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

3060

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Lauren Kane, MSc, BSc
  • Phone Number: 77866 905-521-2100
  • Email: kanela@hhsc.ca

Study Locations

    • Ontario
      • Hamilton, Ontario, Canada, L8M 1W9
        • Recruiting
        • McMaster University - St. Peter's Hospital
        • Principal Investigator:
          • Alexandra Papaioannou, MD, MSc
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Both profit and non-profit long-term care homes in Ontario, Canada.
  • Homes must have a minimum of 50 occupied beds to participate; there is no maximum home size for participation.
  • For both control and intervention homes, resident eligibility (and study cohorts) will be determined via the RAI-MDS 2.0 database.

Exclusion Criteria:

  • Residents identified as having end-stage disease, who are comatose, receiving hospice or respite care and who have an expected short stay (90 days or less).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Group
Residents in homes allocated to the control group will receive usual care as provided within their home.
Experimental: PREVENT Program
PREVENT model
A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of hip-fractures
Time Frame: One year
Data extracted from the Discharge Abstract Database (DAD) and National Ambulatory Care Reporting System (NACRS). Scored as occurred: yes, no.
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of non-hip fractures (wrist, spine, pelvis, humerus)
Time Frame: One year
Data extracted from the DAD and NACRS datasets. Scored as occurred: yes, no.
One year
Number of hospital transfers (emergency department and admissions)
Time Frame: One year
Data extracted from the DAD and NACRS datasets. Scored as occurred: yes, no.
One year
Number of deaths
Time Frame: One year
Data extracted from the DAD and NACRS datasets. Scored as occurred: yes, no.
One year
Change in number of falls
Time Frame: Baseline, 3, 6, 9 and 12 months
Assessed by the Minimum Data Set (MDS) (standardized assessment) 2.0. Scored as occurred: yes, no and number of falls.
Baseline, 3, 6, 9 and 12 months
Change in level of pain
Time Frame: Baseline, 3, 6, 9 and 12 months
Assessed by the MDS 2.0 Pain Scale. Scored on a scale from 0-4 where higher scores indicate more severe pain.
Baseline, 3, 6, 9 and 12 months
Change in mobility
Time Frame: Baseline, 3, 6, 9 and 12 months
Assessed by the MDS 2.0 Activities of Daily Living (ADL) Hierarchy Scale. Scored on a scale from 0-6 where higher scores indicate more impairment in ADL performance.
Baseline, 3, 6, 9 and 12 months
Change in responsive behaviours
Time Frame: Baseline, 3, 6, 9 and 12 months
Assessed by the MDS 2.0 Aggressive Behaviour Scale. Scored on a scale from 0-12 where higher scores indicate greater frequency and diversity of aggressive behaviour.
Baseline, 3, 6, 9 and 12 months
Change in health related quality of life
Time Frame: Baseline, 3, 6, 9 and 12 months
Assessed by the MDS 2.0 Health Status Index. Scored on a scale from 0-1 where a score of 1 indicates full health.
Baseline, 3, 6, 9 and 12 months
Change in medications
Time Frame: Baseline, 3, 6, 9 and 12 months
Data extracted from the pharmacy database. Recorded as number of LTC residents receiving osteoporosis medication(s).
Baseline, 3, 6, 9 and 12 months
Health quality indicators
Time Frame: Baseline, 3, 6, 9 and 12 months.
Assessed by the Minimum Data Set (MDS) (standardized assessment) 2.0 or health quality indicators for falls, pressure ulcers, pain, physical function and depression.
Baseline, 3, 6, 9 and 12 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alexandra Papaioannou, MD, MSc, McMaster University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 19, 2024

Primary Completion (Estimated)

March 31, 2026

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

June 24, 2021

First Submitted That Met QC Criteria

June 24, 2021

First Posted (Actual)

July 1, 2021

Study Record Updates

Last Update Posted (Estimated)

July 1, 2025

Last Update Submitted That Met QC Criteria

June 27, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoporosis

Clinical Trials on PREVENT Program

Subscribe